Array BioPharma Inc

Find Ratings Reports
ARRY : NASDAQ : Health Care
$11.36 | %
Today's Range: 11.04 - 11.45
Avg. Daily Volume: 4197900.0
01/20/17 - 4:00 PM ET

Financial Analysis


ARRAY BIOPHARMA INC's gross profit margin for the first quarter of its fiscal year 2017 has increased when compared to the same period a year ago. Even though sales increased, the net income has decreased, representing a decrease to the bottom line. ARRAY BIOPHARMA INC is extremely liquid. Currently, the Quick Ratio is 2.35 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has decreased from the same period last year.

At the same time, stockholders' equity ("net worth") has significantly decreased by 316.27% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q1 FY17 Q1 FY16
Net Sales ($mil)39.2716.2
EBITDA ($mil)-23.52-17.9
EBIT ($mil)-24.0-18.37
Net Income ($mil)-28.61-20.99


Balance Sheet Q1 FY17 Q1 FY16
Cash & Equiv. ($mil)116.65159.3
Total Assets ($mil)166.86186.75
Total Debt ($mil)125.55108.81
Equity ($mil)-52.1224.1


Profitability Q1 FY17 Q1 FY16
Gross Profit Margin78.6964.57
EBITDA Margin-59.9-110.5
Operating Margin-61.11-113.42
Sales Turnover0.960.76
Return on Assets-60.28.55
Return on Equity0.066.28
Debt Q1 FY17 Q1 FY16
Current Ratio2.463.65
Debt/Capital1.710.82
Interest Expense2.982.66
Interest Coverage-8.06-6.92


Share Data Q1 FY17 Q1 FY16
Shares outstanding (mil)147.33142.33
Div / share0.00.0
EPS-0.2-0.15
Book value / share-0.350.17
Institutional Own % n/a n/a
Avg Daily Volume3918898.05614618.0

Valuation


SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. Along with this, the price-to-book ratio is also meaningless due to a negative book value for the company, making any comparisons useless. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
ARRY NM Peers 34.33   ARRY NM Peers 27.22

Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.

ARRY's P/E is negative making this valuation measure meaningless.

 

Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

ARRY's P/CF is negative making the measure meaningless.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
ARRY NM Peers 24.82   ARRY NA Peers 0.41

Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.

ARRY's ratio is negative making this valuation measure meaningless.

 

Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

Ratio not available.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
ARRY NM Peers 11.43   ARRY -1100.00 Peers 3.61

Neutral. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

ARRY's P/B is negative making this valuation measure meaningless.

 

Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

However, ARRY is expected to significantly trail its peers on the basis of its earnings growth rate.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
ARRY 9.25 Peers 136.62   ARRY 13.30 Peers 532.92

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

ARRY is trading at a significant discount to its industry on this measurement.

 

Lower. A sales growth rate that trails the industry implies that a company is losing market share.

ARRY significantly trails its peers on the basis of sales growth

 

 

Latest Stock Upgrades/Downgrades